Wu J, et al. - Researchers assessed the effectiveness and safety of denosumab vs bisphosphonates to treat osteoporosis. They searched the published literatures (only including randomized controlled trials) in the following electronic databases: PubMed, Embase, Web of Science, Cochrane Library, and Google database from inception to April 20, 2018. Findings suggested that for postmenopausal osteoporosis patients, a significant increase in the change in total hip, femoral neck, lumbar spine, and one-third radius bone mineral density (BMD) was seen with denosumab, but not bisphosphonates. For reducing the risk of fracture, no benefit of denosumab vs bisphosphonates was seen, as suggested by the current evidence.